- Home
- FLC vs SWKH Comparison
FLC vs SWKH Comparison
Compare FLC & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FLC | SWKH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Trusts Except Educational Religious and Charitable | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 198.4M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | FLC | SWKH |
|---|---|---|
| Price | $16.95 | $16.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 24.9K | ★ 104.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.26 | $13.32 |
| 52 Week High | $18.09 | $17.90 |
Technical Indicators
Market Signals| Indicator | FLC | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 32.19 |
| Support Level | $16.26 | $14.69 |
| Resistance Level | $17.32 | $17.08 |
| Average True Range (ATR) | 0.17 | 0.37 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 19.31 | 12.06 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.